Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy and is highly resistant to standard treatment regimens. Targeted therapies against , a mutation present in an overwhelming majority of PDAC cases, have been largely ineffective. However, inhibition of downstream components in the KR...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular cancer therapeutics 2019-02, Vol.18 (2), p.301-311
Hauptverfasser:	Totiger, Tulasigeri M, Srinivasan, Supriya, Jala, Venkatakrishna R, Lamichhane, Purushottam, Dosch, Austin R, Gaidarski, 3rd, Alexander A, Joshi, Chandrashekhar, Rangappa, Shobith, Castellanos, Jason, Vemula, Praveen Kumar, Chen, Xi, Kwon, Deukwoo, Kashikar, Nilesh, VanSaun, Michael, Merchant, Nipun B, Nagathihalli, Nagaraj S
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antineoplastic Agents, Phytogenic - administration & dosage Antineoplastic Agents, Phytogenic - pharmacology Carcinoma, Pancreatic Ductal - drug therapy Carcinoma, Pancreatic Ductal - metabolism Cell Line, Tumor Cell Proliferation - drug effects Cell Survival - drug effects Coumarins - administration & dosage Coumarins - pharmacology Humans Lythraceae - chemistry Mice Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - metabolism Phosphatidylinositol 3-Kinases - metabolism Phosphorylation - drug effects Proto-Oncogene Proteins c-akt - metabolism Signal Transduction - drug effects TOR Serine-Threonine Kinases - metabolism Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!